The EGFR T790M somatic mutation is the most common mechanism of resistance to tyrosine kinase inhibitors in NSCLC. Patients with advanced disease are not always amenable to repeat biopsy for further molecular analysis. Developing noninvasive methods to detect T790M in cell-free DNA in the absence of tissue is being actively investigated. Unfortunately, the low sensitivity of plasma for detection of T790M has limited its clinical use. Exhaled breath condensate (EBC) is an easily collected sample that is known to harbor cell-free DNA, including lung cancer mutations. This report details the potential utility of exhaled breath condensate in the detection of the EGFR T790M mutation.
Introduction
Lung cancer classification is increasingly based on the detection of tumor-specific genetic changes. Testing for EGFR mutations is the current standard of care in advanced lung adenocarcinoma. 1 These tumor mutations are found in approximately 17% of white patients, with a higher prevalence in Asians, females, and neversmokers, 2 When EGFR mutations are present, overall survival is markedly improved with tyrosine kinase inhibitor therapy; however, treatment resistance ultimately develops in all cases, and in slightly more than half of patients it is due to emergence of the secondary EGFR T790M mutation in the tumor. 3 Osimertinib targets EGFR T790M effectively, with a response rate of 61%, and it extends progression-free survival in patients with EGFR T790M-positive lung cancer. 4 Currently, detection of EGFR T790M requires a repeat tumor biopsy. This is often impractical, frequently results in an insufficient sample, and has accompanying morbidity for the patient. 5 A less invasive approach to detect and track EGFR T790M in the cell-free DNA of plasma and urine is possible, albeit with limitations. 6, 7 A commercially available plasma-based assay has shown lower sensitivity for detection of EGFR T790M than other EGFR mutations, and this has somewhat limited its introduction into routine clinical practice. 8 Exhaled breath condensate (EBC) is the liquid form of expired air. It is a noninvasive, organ-specific, acellular biofluid that is derived from airway lining fluid and is known to be a source of lung cancer-specific DNA. 9, 10 Samples can be obtained even in patients with airflow limitation with no effect on the volumes collected. A considerable body of research into the relationship between the volatile organic compound component of exhaled breath (including its ability to discern the mutation status of lung cancer cell lines in in vitro studies) and the detection of lung cancer has been published. 11 Recent reports have also shown that breath analysis using the gas chromatography mass spectrometry and nanoarray approach can detect treatment response and distinguish tumors with EGFR mutation from wild-type tumors with a high degree of accuracy. 12, 13 Low concentrations of cell-free DNA in EBC have necessitated large volumes of sample, which in turn require long collection times. We investigated the potential of EBC for detection of the EGFR T790M mutation in the EBC DNA of patients with EGFR mutation-positive lung cancer by using small volumes of EBC and analyzing them with commercially available technology.
Methods
After institutional review board approval and informed written consent, we collected matched EBC and plasma samples from 19 patients with stage IV EGFR mutation-positive lung adenocarcinoma. Patients were recruited consecutively from three national cancer centers over a 12-month period (2016-2017). Ten patients had confirmed EGFR T790M disease progression and were recruited before commencement of osimertinib therapy. Nine patients with sensitizing EGFR mutations but not EGFR T790M in their tumors served as controls. Each patient's lung cancer mutation status was confirmed by real-time polymerase chain reaction assay (cobas analysis [Roche Diagnostics, Indianapolis, IN) of tumor tissue.
EBC was collected by using an RTube breath condensate collection device (Respiratory Research, Inc., Austin, TX) with the cooling sleeve at -70 C. Patients breathed into the RTube for 10 minutes at tidal breathing. Samples were then snap-frozen at -80 C. At the same time, plasma was collected in 9 mL of ethylenediaminetetraacetic acid (EDTA)-filled tubes and centrifuged; all the samples were stored at -80 C within 2 hours of collection. Samples were collected from each patient contemporaneously. DNA from the EBC samples was extracted by using the Qiagen DNA Blood Mini Kit (Qiagen, Valencia, CA), and DNA from plasma samples was extracted by using the Norgen Cell Free DNA plasma kit (Norgen Biotek, Thorold, Ontario, Canada). The DNA extracted from the plasma and EBC samples for each patient were analyzed by using UltraSEEK on the Agena MassARRAY (Agena Bioscience GmbH, Hamburg, Germany). UltraSEEK technology is based on the same detection principles as standard matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, but with critical modifications that allow a significant increase in the sensitivity of detection of mutant alleles. 14 Unlike in the iPLEX reaction, the extension reaction mixture of UltraSEEK contains only the mutant dideoxynucleotide as a chain terminator; consequently, no wild type product is generated. Semiquantitative assessment of the mutation allele frequency is inferred, facilitating mutation allele frequencies in the 0.1% to 10% dynamic range.
Results
The mean age of the 19 patients was 63.6 years (range 39-80). There were nine males and 10 females. Other baseline patient characteristics are described in Table 1 . Nine of 10 EBC samples from the EGFR T790M-positive cases harbored the EGFR T790M mutation, whereas only seven of the 10 plasma samples were positive (representative outputs are shown in Fig. 1) . Interestingly, our single false-negative EBC result was obtained from a patient with minimal lung tumor burden, progression of disease in the abdomen, and T790M analysis from a paraaortic node biopsy. Conversely, the three false-negative plasma samples had stable extrathoracic disease with progression in a lung mass or mediastinal node. None of the EBC or plasma samples from the nine control patients had the EGFR T790M mutation.
Conclusion
To our knowledge, our group is the first to report detection of the EGFR T790M mutation in the DNA of EBC. This is potentially an important finding given that the vast majority of research in this area to date has been based on blood. The current imperfect sensitivity of plasma for detection of EGFR T790M mutation is likely due to high levels of wild-type genomic DNA masking the less abundant mutant allele and to blood's inherently high nuclease activity. EBC is acellular and therefore may contain lower levels of wild-type DNA, with far lower levels of endogenous nuclease in lung than in blood. 15 Because EBC is an organ-specific biofluid, it is also biologically plausible that it may be of particular benefit in metastatic disease confined to the chest, which is an area where plasma sensitivity is lowest. 8 Although the sample size in our study was small and insufficient for formal statistical analysis, our findings are suggestive. All of the patients were correctly genotyped with a combination of both EBC and plasma analysis. Further research to validate the role of EBC as an alternative or adjunct to plasma testing for the detection of EGFR T790M in patients with EGFR mutation-positive lung cancer is now needed. 
